EP3727365A2 - Formulations à libération modifiée de flurbiprofène - Google Patents

Formulations à libération modifiée de flurbiprofène

Info

Publication number
EP3727365A2
EP3727365A2 EP18916470.0A EP18916470A EP3727365A2 EP 3727365 A2 EP3727365 A2 EP 3727365A2 EP 18916470 A EP18916470 A EP 18916470A EP 3727365 A2 EP3727365 A2 EP 3727365A2
Authority
EP
European Patent Office
Prior art keywords
release phase
pharmaceutical formulation
formulation according
sustained release
flurbiprofen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18916470.0A
Other languages
German (de)
English (en)
Other versions
EP3727365A4 (fr
Inventor
Ali TÜRKYILMAZ
Nur PEHLIVAN AKALIN
Kerim AKKAYA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of EP3727365A2 publication Critical patent/EP3727365A2/fr
Publication of EP3727365A4 publication Critical patent/EP3727365A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 

Definitions

  • the present invention relates to pharmaceutical formulations of flurbiprofen or a pharmaceutically acceptable salt thereof comprising an immediate release phase and a sustained release phase.
  • Flurbiprofen is a propionic acid derivative which is an NSAID (non-steroidal anti inflammatory drug), having analgesic and anti-inflammatory activities. Its chemical structure is illustrated with Formula 1 given below.
  • Flurbiprofen is used for alleviating pain in muscle-skeleton system and joint disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis, in soft tissue injuries such as sprains and strains, in postoperative cases, and in painful severe menstruation and migraine. It is in the market under the brandname of ANSAID ® in strength of 50, 100, 200 and 300 mg. It is recommended 2, 3 or 4 times a day dose.
  • the major adverse reactions with flurbiprofen are those affecting the gastrointestinal tract (GIT) including peptic and mucosal ulcer, dyspepsia, gastric bleeding resulting in treatment failures.
  • GIT gastrointestinal tract
  • Non-compliance of patients and its short half-life make it a strong candidate for sustained drug delivery.
  • the application WO 98/52545 relates to pharmaceutical compositions comprising a formulation of flurbiprofen with a therapeutically effective amount of one or more active ingredients selected from an antihistamine, a cough suppressant, a decongestant, an expectorant, a muscle relaxant, a centrally acting analgesic, a local anesthetic, an antibacterial compound, an antiviral compound, an antibiotic compound, an antifungal compound, minerals and vitamins and/or a burn-masking amount of an agent which has a warming effect on the mucosa of the throat.
  • active ingredients selected from an antihistamine, a cough suppressant, a decongestant, an expectorant, a muscle relaxant, a centrally acting analgesic, a local anesthetic, an antibacterial compound, an antiviral compound, an antibiotic compound, an antifungal compound, minerals and vitamins and/or a burn-masking amount of an agent which has a warming effect on the mucosa of the throat.
  • the patent US05807568 discloses a topically-administered formulation comprising flurbiprofen as the active agent.
  • the patent W09523596 discloses a flurbiprofen solution in a C2-4 alcohol.
  • EP2074990 discloses controlled release (CR) flurbiprofen and muscle relaxant combinations for oral administration.
  • flurbiprofen in treating local pains and inflammations may cause a problem especially for those who have gastrointestinal system disorders. Flurbiprofen leads to a complaint in the form of burning sensation in the gastrointestinal system. Preventing the systemic side effects of flurbiprofen is quite important in terms of patient compliance. Various coating processes have been performed to prevent such side effects. The coatings, however, may cause problems in terms of solubility and thus bioavailability. Enhancing the absorption rate both provides ease of application and increases the molecule's efficiency.
  • flurbiprofen Another problem in relation to flurbiprofen is that this molecule is poorly soluble in water. This, in turn, directly effects the bioavailability, and therefore the solubility and dissolution rate have to be increased.
  • the composition should also be very stable because an immediate release due to accidental damaging of capsule of a high dosage form may result in undesired high plasma concentrations, so-called dose dumping, which could cause undesired side effects.
  • the release rate and the release pattern of the active drug substance from the composition should not significantly change during the shelf-life of the composition. Even a minor change in the release rate and/or release pattern may have a significant impact on the in vivo performance of the composition
  • stability problems are frequently encountered in formulations developed with flurbiprofen under the influence of environmental and physical conditions. Flurbiprofen is an active agent that is highly-susceptible to air and humidity conditions. When flurbiprofen is initially exposed to air and humidity, it degrades structurally and develops chemical behavioral changes.
  • the first problem is that the stability of the products developed is not at a desired level and the shelf life thereof is shortened.
  • flurbiprofen may react with the excipients employed in developing those formulations containing the same. This, in turn, causes impurities and unwanted components to be included into the formulation. Thus, it is important to choose excipients and use them in specific amounts that sustain the stability.
  • Flurbiprofen is presented in many capsule and tablet formulations. This active pharmaceutical agent used for treating many diseases, is preferred in pharmaceutical compositions with sustained or immediate release form. Flowever, although there are sustained release compositions of flurbiprofen in the market, none of them have sustained and immediate release phases in one dosage form.
  • modified release formulation of flurbiprofen in a suitable pharmaceutical dosage formulation is needed.
  • a novelty is required in the art of formulations having anti-inflammatory, analgesic, and antipyretic activities due to the aforesaid drawbacks.
  • a formulation has been developed as to combine an immediate release phase and sustained release for flurbiprofen.
  • An object of this present invention is to provide a pharmaceutical formulation making the plasma concentration level stable by maintaining release of flurbiprofen in the blood stream for a longer time period sufficient to justify once daily dosing and thus increases patient compliance.
  • Another object of the present invention is to provide a pharmaceutical formulation maintaining the therapeutic effect due to the sustained release of flurbiprofen over extended period of time that increases patient compliance.
  • An object of this present invention is to provide a pharmaceutical formulation of flurbiprofen or a pharmaceutically acceptable salt thereof comprises an immediate release phase and a sustained release phase.
  • an object of the present invention is to obtain at least one stable formulation with anti-inflammatory, analgesic, and antipyretic activities.
  • Another object of the present invention is to provide a formulation having a desired solubility and dissolution rate, and therefore a desired level of bioavailability, with this formulation comprising flurbiprofen.
  • Another object of the present invention is to obtain a uniform formulation content.
  • a further object of the present invention is to develop a formulation not leading to flowability problems during production.
  • Another object of the present invention is to provide a high disintegration rate for said formulation.
  • the present invention provides flurbiprofen formulations, eliminating all problems referred to above and bringing additional advantages to the relevant prior art.
  • the present invention relates to a pharmaceutical formulation of flurbiprofen or a pharmaceutically acceptable salt thereof comprising an immediate release phase and a sustained release phase that provides such therapeutic relief by releasing flurbiprofen in such a manner that dose dumping is prevented and requisite blood levels are maintained for an extended time period sufficient to justify once daily dosing and thus increase patient compliance.
  • compositions of flurbiprofen or a pharmaceutically acceptable salt thereof comprise an immediate release phase and a sustained release phase, wherein the sustained release phase is in the form of pellets.
  • the sustained release phase is in the form of pellets
  • the release profile of flurbiprofen is almost stable.
  • Selection of pellets as the sustained release phase dosage form enables the sustained release pharmaceutical formulation of flurbiprofen of the present invention to be more advantageous over the prior art and to be successful in achieving the desired release profile of flurbiprofen.
  • the immediate release phase is in the form of powder, tablet, capsule, granule, bead or pellet.
  • the immediate release phase in the form of powder.
  • the pharmaceutical formulation is in the form of capsule.
  • Enclosing the medication within capsule shells provides a tasteless, odourless means of administering medication. Capsules ease to swallow due to the fact that it is smooth, slippery. Combining immediate and sustained release phases in a capsule dosage form increases patient compliance and also prevents the systemic side effects of flurbiprofen without the need for coating process. The coatings in priort art may cause problems in terms of solubility and thus bioavailability.
  • sustained release phase refers to any pharmaceutical formulation that maintain constant levels of a drug in the patient's bloodstream by releasing the drug over an extended period of time. Sustained release phase is formulated to release the active ingredient gradually and predictably over a 12-hour to 24-hour period.
  • immediate release phase refers to any pharmaceutical formulations that disintegrate rapidly after administration with enhanced rate of dissolution and get dissolved to release the medicaments.
  • the amount of flurbiprofen in the immediate release is between 30.00% and 70.00%, preferably between 40.00% and 60.00%, more preferably between 45.00% and 55.00% by weight of the immediate release phase.
  • the amount of flurbiprofen in the sustained release phase is between 30.00% and 90.00%, preferably between 40.00% and 80.00%, more preferably between 55.00% and 70.00% by weight of the sustained release phase.
  • the ratios of the active agent used in this present invention ensure the required effective doses for the treatment and desired release profiles, which are immediate release and sustained release, for flurbiprofen.
  • the sustained release phase comprises at least one rate controlling polymer which is selected from the group comprises ammonioalkyl methacrylate copolymer dispersion type A, ammonioalkyl methacrylate copolymer dispersion type B polyvinylpyrrolidone, polyvinyl acetate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxymethyl cellulose, gelatin, polyethylene oxide, dextrin, polyhydroxyethylmethacrylate, sodium carboxymethylcellulose, carboxymethyl cellulose, sodium alginate, alginic acid, xanthan gum; acrylic acid, carbopol agar, guar gum, psyllium seed gum, gellan gum, ean gum, tara gum, tamarind gum, gum arabic, methylcellulose, chitosan; glycerol, propylene glycol, macrogols, phthalate esters, dibutyl sebacetate, castor oil, acet
  • the sustained release phase comprises at least one rate controlling polymer which is selected from ammonioalkyl methacrylate copolymer dispersion type A, ammonioalkyl methacrylate copolymer dispersion type B or mixtures thereof.
  • the sustained release phase comprises ammonioalkyl methacrylate copolymer dispersion type A and ammonioalkyl methacrylate copolymer dispersion type B as rate controlling polymers.
  • total amount of rate controlling polymers in the sustained release phase is between 1.00% and 40.00%, preferably between 5.00% and 30.00%, more preferably between 10.00% and 20.00% by weight of the sustained release phase.
  • rate controlling polymer refers to an excipient in the final dosage form whose primary function is to modify the duration of release of the active drug substance from the dosage form. Selection of the rate controlling polymers is an important factor for providing an efficient and desired release kinetic. When the rate controlling polymers are used in speceific amounts, the release of flurbiprofen is maintained over a more extended period of time.
  • flurbiprofen or a pharmaceutically acceptable salt thereof is present in an amount of between 10 mg and 300 mg in the formulation.
  • the pharmaceutical formulation releases immediately flurbiprofen to provide sufficient blood concentration in a short time for starting therapeutic effect by means of immediate release phase and it provides release of flurbiprofen for a long duration by means of sustained release phase to maintain required effective blood concentration for the therapeutic effect. Therefore, the sustained release pharmaceutical formulation makes the plasma concentration level stable by maintaining release of flurbiprofen in the blood stream for a longer time period sufficient to justify once daily dosing and this increases patient compliance. Also, reduction of a dose regimen enables fluctuations of the active ingredient concentration in the blood plasma to be prevented.
  • Immediate release phase of said formulation provides rapid release of flurbiprofen after administration to provide sufficient blood concentration in a short time for starting therapeutic effect.
  • Sustained release of flurbiprofen is achieved by the sustained release phase of said formulation to make the plasma concentration level stable by maintaining flurbiprofen in the blood stream for a longer time. Therefore, the release profile of flurbiprofen in sustained release phase is very important to maintain the therapeutic effect.
  • At least one pharmaceutically acceptable excipient which is selected from a group comprising binders, disintegrants, fillers, plasticizers, adsorbents, lubricants and glidants or mixtures thereof.
  • the binder is selected from the group comprising hydroxypropyl cellulose, polyethylene oxide, microcrystalline cellulose (PH 101 , PH 102), polyvinylpyrrolidone, crospovidon, sugars, glycose syrups, natural gums, guar gum, gelatins, pullulan, agar, alginate, sodium alginates, K-Carrageenan, glycyrrhizin, polymetacrylates, collagen, agar, hyaluronic acid, pectin, tragachanti gum, carboxymethyl cellulose, polyethylene glycol, polyvinyl alcohol, polyvinyl acetate and their copolymers, hydroxypropyl methyl cellulose, carboxy methyl cellulose, methyl cellulose, polyvinylalcohol, carrageenan, carbomer, poloxamer, polyacrylamide, aluminum hydroxide, benthonite, laponite, setostearyl alcohol, polyoxyethylene-alkyl ethers
  • the binder in the immediate release phase is hydroxypropyl cellulose.
  • the amount of binder is between 0.50% and 20.00%, preferably between 1.00% and 15.00%, more preferably between 1 .00% and 10.00% by weight of the immediate release phase.
  • Suitable diluents are selected from the group comprising microcrystalline cellulose, lactose, lactose monohydrate mannitol, spray-dried mannitol, starch, dextrose, sucrose, fructose, maltose, sorbitol, xylitol, inositol, kaolin, inorganic salts, calcium salts, polysaccharides, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof.
  • the diluent in the sustained release phase is microcrystalline cellulose.
  • the amount of diluent in the sustained release phase is between 10.00% and 40.00%, preferably between 10.00% and 30.00%, more preferably between 15.00% and 25.00% by weight of the sustained release phase.
  • neutral microcrystalline cellulose pellets are used as the diluent in the sustained release phase. Selection of microcrystalline cellulose pellets as the diluent helps to improve the stability of the formulation.
  • the neutral microcrystalline cellulose pellets are coated with a suspension to obtain a sustained release phase in the form of pellets.
  • Coated neutral pellets are obtained by spraying a suspension comprising flurbiprofen into them in a fluid bed dryer.
  • flurbiprofen in the sustained release phase is in a micronized form.
  • the dissolution rate is enhanced by using micronized flurbiprofen.
  • a further advantage of using micronized flurbiprofen is homogeneity of the coating of neutral pellets used herein.
  • the diluent in the immediate release phase is selected from lactose, microcrystalline cellulose or mixtures thereof.
  • the immediate release phase comprises two diluents which are microcrystalline cellulose and lactose.
  • the amount of diluents in the immediate release phase is between 10.00% and 75.00%, preferably between 20.00% and 55.00%, more preferably between 30.00% and 45.00% by weight of the immediate release phase.
  • Suitable disintegrants are selected from the group selected from the group comprising croscarmellose sodium, polyethylene oxide, sodium starch glycolate, microcrystalline cellulose, sodium carboxymethyl starch, soy polysaccharide, cross-linked alginic acid, crospovidone, copovidone, gellan gum, xanthan gum, calcium silicate or ion exchange resins or mixtures thereof.
  • the disintegrant in the immediate release phase is croscarmellose sodium.
  • the amount of the disintegrant in the immediate release phase is between 0.50% and 20.00%, preferably between 1 .00% and 15.00%, more preferably between 1 .00% and 10.00% by weight of the immediate release phase.
  • Suitable plasticizers are selected from a group comprising triethyl citrate, diethyl phthalate, polyethylene glycol, medium chain glycerides, triacetin, acetyltributyl citrate, acetyltriethyl citrate, alpha tocopherol, chlorobutanol, dibutyl sebacate, tributyl citrate or mixtures thereof.
  • the plasticizer in the sustained release phase is triethyl citrate.
  • the amount of plasticizer is between 0.10% and 10.00%, preferably between 0.50% and 7.50%, more preferably between 1.00% and 5.00% by weight of the sustained release phase.
  • Suitable lubricants are selected from magnesium stearate, sodium stearyl fumarate, polyethylene glycol, sodium lauryl sulphate, magnesium lauryl sulphate, fumaric acid, glyceryl palmitostearate, hydrogenated natural oils, zinc stearate, calcium stearate, silica, talc, stearic acid, polyethylene glycol, paraffin or mixtures thereof.
  • the lubricant in the immediate release phase is magnesium stearate.
  • the amount of lubricant is between 0.10% and 10.00%, preferably between 0.10% and 5.00%, more preferably between 0.50% and 1 .00% by weight of the immediate release phase.
  • Suitable glidants are selected from colloidal silicon dioxide, talc, aluminium silicate or mixtures thereof.
  • the glidant in the immediate release phase is colloidal silicon dioxide.
  • the amount of glidant is between 0.10% and 10.00%, preferably between 0.10% and 5.00%, more preferably between 0.50% and 1.00% by weight of the immediate release phase.
  • Suitable adsorbents are selected from the group comprising silicon dioxide, talc or mixtures thereof.
  • the adsorbent is silicon dioxide.
  • the amount of the adsorbent is between 0.10% and 10.00%, preferably between 0.20% and 1 .00% by weight of the sustained release phase.
  • the sustained release phase in the form of pellets comprises micronized flurbiprofen as active agent, microcrystalline cellulose as diluent, triethyl citrate as plasticizer, ammonioalkyl methacrylate copolymer dispersion type A and ammonioalkyl methacrylate copolymer dispersion type B as rate controlling polymers, silicon dioxide as adsorbent.
  • the immediate release phase in the form of powder comprises flurbiprofen as active agent, lactose and microcrystalline cellulose as diluent, croscarmellose sodium as disintegrant, hydroxypropyl cellulose as binder, colloidal silicon dioxide as glidant and magnesium stearate as lubricant.
  • the sustained release phase of the formulation comprises;
  • microcrystalline cellulose 10.00% to 40.00%
  • ammonioalkyl methacrylate copolymer dispersion type A 0.50% to 20.00%
  • ammonioalkyl methacrylate copolymer dispersion type B 0.50% to 20.00%
  • silicon dioxide 0.10% to 10.00%
  • the immediate release phase of the formulation comprises;
  • microcrystalline cellulose 15.00% to 50.00%
  • Neutral pellets comprise microcrystalline cellulose.
  • Neutral pellets comprise microcrystalline cellulose.
  • the pharmaceutical formulations mentioned above are prepared by following these steps:
  • ammonioalkyl methacrylate copolymer dispersion type B to the suspension and mixing for 2-3 hours

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des formulations pharmaceutiques de flurbiprofène ou d'un sel pharmaceutiquement acceptable de celui-ci comprenant une phase à libération immédiate et une phase à libération prolongée.
EP18916470.0A 2017-12-21 2018-12-20 Formulations à libération modifiée de flurbiprofène Pending EP3727365A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2017/21036A TR201721036A2 (tr) 2017-12-21 2017-12-21 Flurbi̇profeni̇n modi̇fi̇ye salimli formülasyonlari
PCT/TR2018/050846 WO2019209217A2 (fr) 2017-12-21 2018-12-20 Formulations à libération modifiée de flurbiprofène

Publications (2)

Publication Number Publication Date
EP3727365A2 true EP3727365A2 (fr) 2020-10-28
EP3727365A4 EP3727365A4 (fr) 2021-06-16

Family

ID=67901210

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18916470.0A Pending EP3727365A4 (fr) 2017-12-21 2018-12-20 Formulations à libération modifiée de flurbiprofène

Country Status (3)

Country Link
EP (1) EP3727365A4 (fr)
TR (1) TR201721036A2 (fr)
WO (1) WO2019209217A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023244502A1 (fr) * 2022-06-13 2023-12-21 Soin Therapeutics Llc Méthodes d'utilisation de naltrexone à faible dose pour traiter une douleur chronique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4140184C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Akutform für ein Flurbiprofen enthaltendes Arzneimittel
DE4140183C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Retardform für ein Flurbiprofen enthaltendes Arzneimittel
EP1064938A1 (fr) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Formes pharmaceutiques à libération contrôlée avec au moins une impulsion temporelle
JP5345620B2 (ja) * 2007-08-15 2013-11-20 マクニール−ピーピーシー・インコーポレーテツド 即時放出及び徐放型イブプロフェンの投与法
EP3209285A1 (fr) * 2014-10-21 2017-08-30 Reckitt Benckiser LLC Capsule pharmaceutique contenant au moins deux comprimés

Also Published As

Publication number Publication date
WO2019209217A2 (fr) 2019-10-31
WO2019209217A3 (fr) 2020-01-23
EP3727365A4 (fr) 2021-06-16
TR201721036A2 (tr) 2019-07-22

Similar Documents

Publication Publication Date Title
ES2606463T3 (es) Combinación de formas de dosificación de levodopa/carbidopa de liberación inmediata y liberación controlada
WO2011151708A1 (fr) Formes posologiques à rétention gastrique d'analogues de gaba
KR101156054B1 (ko) 안정한 에페리손 함유 서방성 의약조성물
EP2797584A2 (fr) Combinaisons de diacéréine et d'anti-inflammatoires non stéroïdiens
US7303761B2 (en) Stabilised pharmaceutical composition comprising an extended release non-steroidal anti-inflammatory agent and an immediate release prostaglandin
WO2014209087A1 (fr) Préparation composite pour gélule pharmaceutique comprenant du tadalafil et de la tamsulosine
KR20120033557A (ko) 레보드로프로피진을 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물
KR20190092805A (ko) 아세틸살리실산 및 란소프라졸을 포함하는 약학적 조성물
JP2019532960A (ja) エソメプラゾール含有複合カプセル剤及びその製造方法
KR20160076928A (ko) 푸마르산 에스테르를 함유하는 미니-정제 형태의 약제학적 제제
EP3727365A2 (fr) Formulations à libération modifiée de flurbiprofène
EP2793854B1 (fr) Formulations de flurbiprofène et de diacéréine
JP2010511023A (ja) メマンチンの製剤組成物
EP2809305B1 (fr) Formulations pour comprimés bicouches de flurbiprofène et glucosamine
KR20160105662A (ko) 에페리손과 펠루비프로펜을 함유하는 약제학적 조성물
EP2277511B1 (fr) Composition pharmaceutique de levetiracetam à libération prolongée
EP2793856B1 (fr) Formulations de flurbiprofène à désintégration orale
WO2016130094A1 (fr) Composition pharmaceutique contenant de l'ibuprofène, une pseudo-éphédrine et de la vitamine c
WO2019212426A2 (fr) Composition de dexkétoprofène à libération retardée
EP2793855B1 (fr) Formulations de flurbiprofène
KR20090107960A (ko) 심혈관계 질환 치료용 약제학적 제제
JP6855387B2 (ja) 圧縮成型製剤
WO2014167439A1 (fr) Compositions pharmaceutiques à libération modifiée de topiramate ou de sels de celui-ci
EP2797583B1 (fr) Formulation pharmaceutique combinée contenant de la diacéréine
KR101037808B1 (ko) 가용화된 니플루믹산을 함유하는 서방성 정제

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200718

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210514

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/192 20060101AFI20210508BHEP

Ipc: A61K 9/48 20060101ALI20210508BHEP

Ipc: A61K 9/50 20060101ALI20210508BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230629

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230708